StockData
Theriva Biologics, Inc. logo

Theriva Biologics, Inc. (TOVX) stock

TOVXNYSEPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 12, 2026Score 4/30
$0.14+0.00 (0.00%)

Close on Nov 17, 2026Market cap $6.42MP/E –Yield –

Theriva Biologics r&d expenses

Research and development expenses are spending on new products and technology.

Theriva Biologics's R&D Expenses for the twelve months ending Jun 30, 2026 was $5.31M, down 49.7% year over year. For fiscal 2025 it was $8.60M, down 28.5% from the year before. Over ten years it grew -12.6% a year on average. The highest annual figure on record is $32.91M in fiscal 2015.

Annual r&d expenses

PeriodPeriod endValueChange
FY2025Dec 31, 2025$8.60M-28.5%
FY2024Dec 31, 2024$12.03M-15.9%
FY2023Dec 31, 2023$14.31M+22.1%
FY2022Dec 31, 2022$11.72M+50.3%
FY2021Dec 31, 2021$7.80M+52.0%
FY2020Dec 31, 2020$5.13M-53.7%
FY2019Dec 31, 2019$11.08M-6.4%
FY2018Dec 31, 2018$11.84M-36.9%
FY2017Dec 31, 2017$18.78M-35.5%
FY2016Dec 31, 2016$29.11M-11.5%
FY2015Dec 31, 2015$32.91M+127.1%
FY2014Dec 31, 2014$14.49M+122.7%
FY2013Dec 31, 2013$6.51M-47.0%
FY2012Dec 31, 2012$12.29M+267.9%
FY2011Dec 31, 2011$3.34M+111.4%
FY2010Dec 31, 2010$1.58M–

Quarterly r&d expenses

Change is against the same quarter a year earlier.

PeriodPeriod endValueChange
Q2 FY2026Jun 30, 2026$1.27M-35.1%
Q1 FY2026Mar 31, 2026$355.00K-88.0%
Q4 FY2025Dec 31, 2025$1.13M-60.8%
Q3 FY2025Sep 30, 2025$2.55M-6.7%
Q2 FY2025Jun 30, 2025$1.95M-33.9%
Q1 FY2025Mar 31, 2025$2.97M-14.2%
Q4 FY2024Dec 31, 2024$2.89M-31.2%
Q3 FY2024Sep 30, 2024$2.73M-31.8%
Q2 FY2024Jun 30, 2024$2.95M-5.7%
Q1 FY2024Mar 31, 2024$3.46M+16.2%
Q4 FY2023Dec 31, 2023$4.20M+36.6%
Q3 FY2023Sep 30, 2023$4.01M+55.9%
Q2 FY2023Jun 30, 2023$3.13M-10.1%
Q1 FY2023Mar 31, 2023$2.98M+14.6%
Q4 FY2022Dec 31, 2022$3.07M+10.5%
Q3 FY2022Sep 30, 2022$2.57M+30.3%
Q2 FY2022Jun 30, 2022$3.49M+80.4%
Q1 FY2022Mar 31, 2022$2.60M+132.3%
Q4 FY2021Dec 31, 2021$2.78M+183.9%
Q3 FY2021Sep 30, 2021$1.97M+115.8%
Q2 FY2021Jun 30, 2021$1.93M+20.5%
Q1 FY2021Mar 31, 2021$1.12M-31.6%
Q4 FY2020Dec 31, 2020$979.00K-49.2%
Q3 FY2020Sep 30, 2020$914.00K-77.9%
Q2 FY2020Jun 30, 2020$1.60M-38.2%
Q1 FY2020Mar 31, 2020$1.64M-32.4%
Q4 FY2019Dec 31, 2019$1.93M-6.3%
Q3 FY2019Sep 30, 2019$4.14M+45.6%
Q2 FY2019Jun 30, 2019$2.59M-27.4%
Q1 FY2019Mar 31, 2019$2.42M-28.2%
Q4 FY2018Dec 31, 2018$2.06M-45.3%
Q3 FY2018Sep 30, 2018$2.85M-31.2%
Q2 FY2018Jun 30, 2018$3.57M-26.1%
Q1 FY2018Mar 31, 2018$3.37M-44.4%
Q4 FY2017Dec 31, 2017$3.76M-44.2%
Q3 FY2017Sep 30, 2017$4.14M-41.4%
Q2 FY2017Jun 30, 2017$4.83M–
Q1 FY2017Mar 31, 2017$6.06M–
Q4 FY2016Dec 31, 2016$6.73M–
Q3 FY2016Sep 30, 2016$7.06M–

More Theriva Biologics figures

See a number that looks wrong?